MOTS-c
Mitochondrial Open Reading Frame of the 12S rRNA Type-c
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A 16-amino-acid peptide encoded within mitochondrial DNA, discovered in 2015. Studied for its roles in metabolic regulation, insulin sensitivity, and longevity biology. Often discussed as a potential exercise-mimetic compound due to its overlapping effects with physical activity at the cellular level.
Plain English
Researchers study MOTS-c because it is produced within mitochondria — the energy-generating structures inside cells — and appears to travel to the cell's nucleus to help the body respond to metabolic stress. Scientists are interested in its potential connections to insulin sensitivity, healthy aging, and the biological pathways activated by exercise. Circulating levels of MOTS-c have been observed to decline with age, which has led researchers to investigate whether this decline plays a role in age-related metabolic changes. It is one of the more recently discovered compounds in the database, and research is still in relatively early stages.
Overview
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene. It is studied as a metabolic stress signal involving AMPK and related pathways. Animal and mechanistic studies examine glucose handling, insulin sensitivity, obesity, exercise, and longevity biology; these findings do not establish human interventional efficacy.
Research Summary
MOTS-c is a mitochondrial-derived peptide discovered as a metabolic stress signal. The cited work is preclinical and examines metabolic homeostasis, obesity, insulin sensitivity, and related exercise biology in animal models. These findings do not establish human efficacy, a self-administration schedule, or a universal pharmacokinetic profile.
Research Areas
- Insulin sensitivity & diabetes
- Metabolic syndrome
- Exercise mimetics
- Longevity & lifespan extension
- AMPK activation
- Obesity
Related Compounds
Safety & Risks
Serious Risks
- Insufficient long-term human safety data; broad AMPK activation has systemic metabolic effects; mechanism not fully characterized in humans
Reported Side Effects
- Generally well-tolerated in animal models
- Mild injection site reactions
- Fatigue (rare, anecdotal in human use)
Legal Status by Region
- United States
- Not FDA approved. The HHS interim 503A policy describes conditional enforcement discretion specifically for MOTS-c acetate in subcutaneous or intramuscular injectable dosage forms, not other forms or routes by inference. This is not proof of safety or effectiveness or blanket compounding legality. The Federal Register notice describes a draft, nonbinding policy; no effective date is asserted here. Conditions include a patient-specific prescription; a State-licensed pharmacy, Federal facility or licensed physician; the exact Appendix B identity and route; FDA-registered original API manufacture compliant with CGMP, valid COAs, required quality testing and supplier validation; reporting compounded products, serious adverse events and quality issues to FDA and relevant States; patient reporting instructions and labeling 'This is a compounded drug product. Not for resale.'; a single Appendix A active ingredient; only a 510(k)-cleared syringe if a delivery device is co-packaged or contains the drug; and all other applicable FD&C Act requirements. This is not a 503B authorization. The interim policy lasts until a final rule addresses the substance and may be revisited for safety or quality signals.
- United Kingdom
- Research only
- Australia
- Research only
- Canada
- Research only
Citations & Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Cell Metabolism · 2015
PMID 25738459 · DOI 10.1016/j.cmet.2015.02.009
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, including Appendices A and B
U.S. Department of Health and Human Services · HHS
- Public inspection notice: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (filed October 28, 2026; scheduled publication October 30, 2026; not an effective-date determination)
U.S. Department of Health and Human Services · Federal Register — Public Inspection
Regulatory FR Doc. 2026-22192